Calyx, a prominent provider of medical imaging services and IRT/RTSM to drug developers, has announced its agreement to acquire Invicro, a leading quantitative imaging biomarker company. This strategic combination, subject to regulatory approvals, is set to establish a new global leader in the provision of medical imaging solutions and development services for the clinical research community. Upon completion, Calyx will acquire 100% of Invicro from its current owner, REALM IDx, Inc., with the transaction anticipated to finalize in Q2 2024.
The merged entity will employ approximately 2,000 skilled professionals across 10 sites worldwide, offering a comprehensive suite of solutions to clients in the pharmaceutical and biotechnology sectors. With deep expertise in supporting over 12,000 clinical and research trials across various therapeutic areas, including oncology and the central nervous system, the combined group will provide enhanced research and development capabilities. Executives from both companies express enthusiasm about the merger, emphasizing the potential to leverage scientific talent, expand service offerings, and collaborate closely with partners to accelerate the development of life-saving therapies across key therapeutic domains. Post-transaction, the focus will be on seamlessly integrating the two companies while ensuring continued high-quality service delivery to customers.
